Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922545 | 0.87 | BCL2A1 (0.41) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL9995135 | 0.85 | ALDH1A1 (0.42) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL12058968 | 0.85 | LMNA (0.47) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL6923330 | 0.82 | KDM4E (0.58) | ALDH1A1LMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6921643 | 0.82 | MEN1 (0.57) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL12059068 | 0.81 | LMNA (0.50) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL12059798 | 0.81 | KDM4E (0.43) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL6920781 | 0.81 | LMNA (0.48) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL6922562 | 0.81 | RAB9A (0.42) | ALDH1A1LMNACYP2C19RAB9ANPC1 | |
| SCHEMBL6922522 | 0.81 | NPC1 (0.48) | ALDH1A1LMNACYP2C19RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | ALDH1A1 1721/4885LMNA 4613/4885CYP2C19 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.